7 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 13 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 7, Recruiting 2, Terminated 2, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow RSV Infection: new trials by email Literature Review of RSV Infection trials Research Report on RSV Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus zelicapavir, Placebo - RSV Infection, RSV | Phase 2 | Recruiting | Enanta Pharmaceuticals, Inc | 150 | 2026-07-09 | 2026-07-20 |
| Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults SCB-1019T, SCB-1022, SCB-1033 - RSV Infection, Human Metapneumovirus Infection | Phase 1 / Phase 2 | Active not recruiting | Clover Biopharmaceuticals AUS Pty | 612 | 2025-06-18 | 2026-10-26 |
| Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection Obeldesivir, Obeldesivir Placebo - RSV Infection | Phase 2 | Terminated | Gilead Sciences | 4 | 2025-03-05 | 2026-06-08 |
| Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection Obeldesivir, Obeldesivir Placebo - RSV Infection | Phase 2 | Terminated | Gilead Sciences | 150 | 2024-10-14 | 2026-06-30 |
| RSV Vaccination in Immunocompromised Patients. Arexvy powder and suspension for injection - RSV Infection | Phase 2 | Recruiting | Medical University of Vienna | 200 | 2024-09-19 | 2024-11-27 |
| A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model EDP-323 Dose Regimen 1, EDP-323 Dose Regimen 2, Placebo - RSV Infection | Phase 2 | Completed | Enanta Pharmaceuticals, Inc | 142 | 2023-11-20 | 2025-10-07 |
| A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV XW001, Placebo - RSV Infection | Phase 1 / Phase 2 | Completed | Hangzhou Sciwind Biosciences Co., Ltd. | 61 | 2023-04-20 | 2025-08-17 |
| A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. EDP-938, Placebo - RSV Infection | Phase 2 | Completed | Enanta Pharmaceuticals, Inc | 187 | 2022-11-29 | 2026-08-19 |
| Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults MVA-mBN294B, Placebo - RSV Infection | Phase 2 | Completed | Bavarian Nordic | 73 | 2021-02-22 | 2023-07-21 |
| Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine MV-012-968, Placebo - RSV Infection | Phase 2 | Completed | Meissa Vaccines, Inc. | 60 | 2020-12-29 | 2022-08-04 |
| Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children Nirsevimab - RSV Infection | Phase 2 | Completed | AstraZeneca | 100 | 2020-08-19 | 2023-11-15 |
| Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV RV521 oral tablet, Placebo oral tablet - RSV Infection, Stem Cell Transplant Complications | Phase 2 | Withdrawn | Pfizer | 2020-06-15 | 2023-05-08 | |
| A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model EDP-938 Dose 1, EDP-938 Dose 2, Placebo - RSV Infection | Phase 2 | Completed | Enanta Pharmaceuticals, Inc | 179 | 2018-10-15 | 2022-05-03 |
Respiratory Syncytial Virus Infections (13) · Paramyxoviridae Infections (1) · Respiratory Tract Infections (1)
Infections (13) · Mononegavirales Infections (13) · Pneumovirus Infections (13) · RNA Virus Infections (13) · Virus Diseases (13) · Paramyxoviridae Infections (12) · Respiratory Tract Diseases (1)
EDP-938 (1) · Injections (1) · Sodium Chloride (1) · Suspensions (1) · XW001 (1) · nirsevimab (1) · sisunatovir (1)
Enanta Pharmaceuticals, Inc (4) · Gilead Sciences (2) · AstraZeneca (1) · Bavarian Nordic (1) · Clover Biopharmaceuticals AUS Pty (1) · Hangzhou Sciwind Biosciences Co., Ltd. (1) · Medical University of Vienna (1) · Meissa Vaccines, Inc. (1) · Pfizer (1)
United Kingdom (5) · United States (4) · Japan (2) · Poland (2) · South Africa (2) · Spain (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Bulgaria (1) · China (1) · Colombia (1) · Czechia (1) · Malaysia (1)
Christopher D Rook, MD (1) · Hanmin Liu, Dr (1) · Mariya Kalinova, MD (1) · Oliver Medzihradsky, MD MPH MS (1) · Qin Yu (1)